Abstract 4407: Neutralizing monoclonal antibody to periostin (PN) inhibits ovarian tumor metastatic growth in animal models

• Published in: Cancer research (Chicago, Ill.) Ill.), 2010-04, Vol.70 (8_Supplement), p.4407-4407
• Main Authors: Zhu, Min, Saxton, Romaine E., Ramos, Lillian, Chang, David D., Karlan, Beth Y., Gasson, Judith C., Slamon, Dennis J.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM10-4407

Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor angiogenesis and metastasis. Our previous results show that engineered PN overexpression promotes ovarian tumor growth and dissemination in vivo. In the present study, we developed a neutralizing monoclonal antibody to PN, named MZ-1, and have investigated its effects on human ovarian tumor cell metastasis and progression. MZ-1 markedly reduced tumor metastatic growth in orthotopic ovarian tumor models derived from two PN-expressing ovarian cancer cell lines A2780 and TOV-112D. These in vivo antitumor effects of MZ-1 were attributed to its specific inhibition of anchorage-independent growth and survival of PN-expressing cells, as well as its neutralization on PN-induced migration. The data suggests that blocking PN expression may be a novel approach for treatment of ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4407.